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Abstract. Depression is one of the most prevalent psychiatric disorders with significant lifetime preva-
lence. The study of human depression is hindered by the relatively significant heterogeneity of this dis-
order. As a result of these heterogeneities, studies using a sound and representative animal model of de-
pression are extremely valuable and, in general, provide important information regarding the neurochemi-
cal/biological changes occurring during depression and the subsequent treatment of its symptoms. In this 
review we concentrate on two solid rat models of depression: olfactory bulbectomized (OBX) rats and 
Flinders Sensitive Line (FSL) of rats. These two models were selected because they possess all three cha-
racteristics of a good animal model; face, predictive and constructive validities. We also emphasize the 
brain serotonergic system and we discuss the open field and forced swim test to assess behaviour. (doi: 
10.5562/cca1817) 
Keywords: depression, olfactory bulbectomized rat model of depression, Flinders sensitive line rat, Flind-
ers Resistant line rat, animal model of depression 
 
INTRODUCTION 
Depression is a brain disorder which produces major 
disability. Its aetiology and mechanisms are not yet well 
understood. According to different reports, the lifetime 
prevalence of depression ranges between a few percent1 
to as much as 15–20 %.2 In addition, depression has not 
yet been associated with any specific and sensitive 
structural alterations of the brain, and there is no bio-
marker of the disorder. Its diagnosis is generally estab-
lished based on the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV),3 but the term “depression” 
actually represents a number of disorders, including 
major depressive disorders. The disease is manifested 
by a loss of interest in pleasure (anhedonia), feelings of 
guilt, depressed mood, disruption of sleep and/or appe-
tite, low energy, poor concentration and suicidal ide-
ations and attempts. It should be noted that not all of the 
aforementioned symptoms have to be present in a single 
patient. Further, depression is a collection of heteroge-
neous symptoms and neurochemical alterations that 
result in several hypotheses/theories of the underlying 
mechanisms. For example, deficiencies in dopaminer-
gic4 and/or the serotonergic functions5 are parts of the 
so-called monoamine theory of depression. Because 
anhedonia and loss of motivation are core features of 
depression, it has been proposed that a disturbance in 
the brain reward system may be involved in the patho-
genesis of major depression.6 Also, the aetiology of 
depression has been correlated to stress, as well as ge-
netic factors. However, no single gene has been discov-
ered, suggesting that the development of depression is a 
consequence of the complex interplay between multi-
genic-inherited susceptibility and environment.7 The 
study of depression in the human population is therefore 
very difficult. Animal models of depression have been 
used to overcome some of these challenges.  
Several review papers have been published on 
animal models of depression.7–10 As is generally the 
case with many different models of human diseases, 
animal models show varying levels of similarities to 
each disease. Accordingly, different animal models have 
been used to study different aspects of these diseases. 
Indeed, there have been other animal models of depres-
sion, based on behavioural despair, reward insensitivity 
or stress, which have been discussed recently in other 
published reviews,8,9 and therefore will not be described 
further here. In a recent review,7 it is clearly stated that 
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models that may be good predictors of an antidepressant 
effect (e.g., learned helplessness, the forced swim and 
tail suspension tests) are nonetheless unrealistic models 
of human depression, as they show behavioural changes 
following acute administration, which is not the case in 
the treatment of human depressive symptoms. Animal 
models of depression need to fulfill three basic criteria:8 
1) face validity (how close the model resembles the 
psychiatric condition); 2) predictive validity (how close 
the action of the drugs in the model resembles the action 
of the drug in humans); and 3) constructive validity (the 
consistency of the model with the theoretical rationale). 
According to the literature,8–10 there are two very sound 
rat models of depression: olfactory bulbectomized mice 
and rats10 and the Flinders Sensitive Line of rats.9 Ac-
cordingly, the present review concentrates on these two 
models. However, there have been numerous models 
investigated, but many of them do not possess all three 
of the above noted characteristics, and, as such, will not 
be discussed in this review. O’Neil and Moore11 wrote: 
“the OBX test is valuable in that it has been one of the 
few tests that mimics the slow onset of antidepressant 
action reported in clinical studies” and concluded that 
“the convergence of data from markers as diverse as 
behaviour, neurochemistry, as well as endocrine and 
immune function, suggest that this model will continue 
to shed valuable light on depressive mechanisms and 
treatment for some time to come”.  
The surgical removal of the olfactory bulbs pro-
duces alterations in many neurotransmitter systems and 
anatomical pathways in the brain, and also produces 
immunological changes.7,10–13 Neuronal changes have 
been reported in structures deemed to play an important 
role in affective and cognitive functioning, which are 
also the target of the olfactory bulb projections, such as 
the amygdala, greater hippocampal formation, and the 
bed nucleus of the stria terminalis.10,14 The amygdala 
and hippocampus have important influences on frontal 
cortical striatal circuitry.15 Similarly, dysfunction of the 
serotonergic and dopaminergic system have been dem-
onstrated in the amygdala of the FSL rats.16,17 There is a 
possibility that chronic sensory deprivation caused by 
the removal of the rat’s most important sensory modal-
ity, olfaction, represents a high intensity stressor. How-
ever, the animals rendered anosmic with zinc sulphate, 
although showing a reduced habitation and enhanced 
reactivity, similar to OBX rats, do not show an increase 
in basal activity level when tested in the open field 
arena, unlike the OBX rats, suggesting that the behav-
iour changes in the OBX rats are independent of anos-
mia.18 
The FSL rats were obtained as outbred by selec-
tive breeding from the Sprague-Dawley (SPD) rats.19,20 
It should be noted that the OBX rats are considered to 
model agitated depression,10,21,22 while the FSL rats 
represent a model of retarded depression.23 In recent 
reviews, these two models have been identified as the 
best for the evaluation of the biochemical characteristics 
of the human depressive state.13,23,24 
It is always questioned which parameters of sero-
tonergic or other neurotransmission one should study in 
an animal model to obtain the best characterization of a 
deficiency related to a disease (e.g., depression), as well 
as the biochemical changes occurring after the elimina-
tion of such deficiencies with treatment. There are many 
parameters that describe, to some extent, serotonergic 
neurotransmission (e.g., 5-HT synthesis, density and 
functionality of different 5-HT receptors, 5-HT trans-
porter, and interaction with the dopaminergic and 
noradrenergic systems), but only a few of them can be 
studied at any given time. For our discussion, we se-
lected the following parameters: (1) 5-HT synthesis, one 
of the most important factors of serotonergic neuro-
transmission;25 (2) 5-HT1A receptors, shown to be impor-
tant in 5-HT synthesis control.26 In addition, the densities 
of these sites are different between the OBX and sham 
operated rats,27,28 as well as between the FSL and control 
FRL rats;29 (3) 5-HT2A receptors, which exhibit differ-
ences between depressed and normal subjects30,31 and 
appear to be affected by the OBX surgery.28,32 Further, 
binding to the 5-HT2A receptors is decreased following 
paroxetine and desipramine treatments in subjects with 
major depression;33,34 (4) Cholinergic, noradrenergic, 
dopaminergic, and GABA-ergic alterations in the FSL 
rats;35–38 and (5) Alteration in second messenger signal-
ling.39 Studies have also shown that 5-HT1A receptors are 
supersensitive in the FSL rats when compared to the 
SPD controls.16,17 Further, 5-HT synthesis has been iden-
tified as a parameter that is affected by OBX40,41 and is 
normalized by antidepressant treatments.27,41  
As noted, we concentrate on the OBX and FSL rat 
models of depression in this review, because our group 
has acquired a substantial volume of data on the sero-
tonergic system in these two models, and that data is not 
available on any other animal model. In addition, these 
two models have been described by others4,10 as the 
most realistic animal models of depression. The major-
ity of the discussion will concentrate on the brain sero-
tonergic system, but other deficiencies and possible 
parallels with human depression will also be discussed. 
 
Olfactory Bulbectomized Rat as a Model of Depression 
The removal of the olfactory bulbs induces neurochemi-
cal, neuroanatomical, physiological, endocrine and 
behavioural changes in rats, which are similar to those 
present in human depression.10 It was shown, more than 
three decades ago, that behavioural changes in olfactory 
bulbectomized (OBX) rats (e.g., hyperactivity, passive 
avoidance and irritability) were reversed following 
chronic antidepressant treatment.42 The relationship 
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between the length of antidepressant treatment and 
time-onset of behavioural normalization in OBX rats 
accords with the findings in depressed patients (it typi-
cally takes a minimum of two weeks for a drug to in-
duce a clinical improvement). This characteristic con-
tributes to the face validity of OBX as a model of de-
pression.43 From that point onwards, OBX was used as a 
model to predict antidepressant characteristics of puta-
tive antidepressant compounds. The utilization of this 
model in biomedical research has now been extended to 
understand many biological changes that are compara-
ble with human depression.44 In addition, endocrine 
changes also present, to some extent, in human depres-
sion (e.g., impaired hypothalamic pituitary-adrenal 
axis10,45,46) were observed in the OBX rats, as was hy-
perphagia with no weight gain,46,47 and altered immune 
functioning and circadian pattern.10,44 Recent research 
showed that physiological changes, such as higher core 
body temperature and decreased heart rate variability, 
occurred 3–5 days post surgery and persisted for a rela-
tively long time, possibly permanently.48 
 
Surgical Procedure and its Subsequent Neuro-
Anatomical Implications  
The surgical procedure of olfactory bulb (OB) removal in 
rats has been previously described in great detail.40,49 In 
brief, Sprague-Dawley (SPD) rats (weighting 200–250 g) 
are anaesthetized with inhalatory anaesthetics, isoflurane 
or halothane, and the small hole is opened on the frontal 
bone, 5.2 mm anterior from the bregma and approxi-
mately 2 mm on both sides from the midline. The olfac-
tory bulbs are visualized with a surgical microscope, cut 
and aspirated with a dull needle attached to a vacuum 
water pump, taking care not to damage the frontal lobes. 
The hole is filled with a hemostatic sponge to prevent 
bleeding and the skin is closed with sutures. The control 
sham-operated rats are operated in the same way, except 
that the olfactory bulbs are not removed. A period of 
two weeks is sufficient for the bulbectomy syndrome to 
develop. A recently described technique of photochemi-
cally induced bulbectomy offers a new possibility in 
inducing OBX syndrome in rats.50  
Olfactory bulbectomy-induced changes, in many 
brain regions, are the result of direct or indirect con-
nectivity of those regions with olfactory bulbs.24,40 
Subsequent extensive changes were referred to retro-
grade, anterograde and transneuronal degeneration, 
including the damages that are a result of vascular 
blood supply deprivation.24 In addition to the bulbec-
tomy-associated axotomy of 5-HT fibres, the re-
organization of 5-HT projections to the forebrain is 
continued by collateral sprouting and synaptogenesis.46 
Furthermore, neuronal degeneration occurs in many 
accessory projection areas (e.g., cortex, hippocampus, 
amygdala, locus coeruleus and raphe nuclei). Structural 
changes in the locus coeruleus and raphe nuclei likely 
underlie the noradrenergic and serotonergic imbalances 
observed in these rats.24 Cortico-hypocampal-amygdala 
circuit changes were reported in humans suffering from 
depression.51 Magnetic resonance imaging studies have 
reported changes in signal intensities in the cortex, hip-
pocampus, caudate and amygdala of OBX rats.52 The 
reduction noted in the hippocampal neurogenesis in the 
OBX rats was reversed by a 28 day treatment with cita-
lopram which increased the proliferation of the neuronal 
progenitors and accelerated the differentiation of the 
progenitors into the adult granule neurons in the dentate 
gyrus. That effect was not found in the sham operated 
animals.53 Others reported a decrease in hippocampal 
volume which correlates with an increase in the ven-
tricular cisterns of the OBX rats.24 Changes in the size 
of the ventricular volume were correlated with the de-
gree of cognitive impairment and memory.24,54 Simi-
larly, Song and Leonard24reported changes within the 
piriform cortex with a reduction in the number of syn-
apses and dendritic spines and shafts in the OBX rats. 
These latter reductions were reversed by chronic anti-
depressant treatment.24 OBX rats have a reduced number 
of tryptophan hydroxylase (TPH)-positive cells in the 
raphe nuclei.55  
 
Behavioural Changes in OBX Rats 
Olfactory bulbectomized (OBX) rats show an alteration 
in normal behaviour.10 Increased activity in an open 
field test is one of the quickest and most consistently 
reported behavioural changes in the OBX rats,10,49,56 
which does not occur as a consequence of the loss of 
smell.42 The lesioning of the serotonergic projections to 
the olfactory bulb lesion (OB) with a local injection of 
the neurotoxin 5,7-dihydroxytrypramine (5,7-DHT) also 
produced hyperactivity in the open field test, which was 
also the case in OBX rats,10,24 suggesting effects of the 
brain serotonergic system on the behavioural changes 
observed in the OBX rats. The hyperactivity was re-
versed by chronic administration of amitryiptyline and 
mianserine. OBX rats showed a deficit in learning to 
avoid the foot shock by remaining on a platform that 
administers electrical shocks longer than the control 
group (passive avoidance test).10,42 The neuronal path-
ways from the OB project directly to the anterior corti-
cal nucleus of the amygdale. The amygdala modulates 
memory processing in other brain regions. Therefore, 
alterations in amygdala functioning are thought to be 
responsible for altered memory processing following 
OBX surgery. Treatment with the cholinesterase inhibi-
tor, physostigmine, and the selective muscarinic (M1) 
agonist, oxotremorine, improved learning and memory 
related behaviour. Furthermore, the choline acetyltrans-
ferase (ChAT) fluorescence was decreased in the hippo-
campus, amygdala and cortex of OBX rats.57 
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Serotonergic System Alterations in OBX Rats 
The first measurement of regional 5-HT synthesis in 
the OBX rats using the α-[14C]methyl-L-tryptophan  
(α-MTrp) autoradiographic method was reported in 
2003.40 The method was previously described,58,59 and 
the details will not be repeated here. Watanabe et al.40 
found increased 5-HT synthesis in the majority of the  
5-HT projection regions in OBX rats, with a synthesis 
reduction in the raphe nuclei, the location of the 5-HT 
neuron cell bodies. The reduction in the synthesis, in 
part, possibly relates to the loss of the cells in the raphe 
following OBX surgery.60 However, the reduction in  
5-HT synthesis could also be related to a direct inhibi-
tion of 5-HT synthesizing enzyme tryptophan hydroxy-
lase (TPH) with the end product, 5-HT, via feedback 
through the 5-HT1A autoreceptors.
40 A chronic treatment 
with citalopram (an SSRI) reduces the 5-HT synthesis 
rate in the OBX rats and brings it to a level comparable 
with the control; sham-citalopram and sham-saline 
rats.41 The 5-HT synthesis rate in the OBX rats treated 
with citalopram was lower in only a few regions relative 
to the sham-saline rats. This is explained by the com-
bined action of higher extracellular levels of 5-HT in 
OBX rats treated with citalopram that acts through the 
autoreceptors (5-HT1A has an inhibitory function on  
5-HT synthesis) that were not fully desensitized in OBX 
rats compared to the sham rats.41 When, in OBX and 
sham operated rats, an acute pindolol (5-HT1A/B antago-
nist) treatment was combined with an acute citalopram 
treatment, 5-HT synthesis in the OBX rats remained 
high in the terminal regions.61 This may be explained by 
the higher responsiveness of the 5-HT1A receptors in the 
OBX rats. As we previously discussed, chronic treat-
ment with citalopram (and other antidepressants) does 
not produce behavioural changes in sham operated rats. 
This correlates to neurochemical findings of 5-HT syn-
thesis.41  
The 5-HT transporter (SERT) studies revealed 
significantly higher SERT densities across many brain 
regions,28 when the OBX rats were compared to the 
sham rats. In accordance with this finding, it was re-
ported that the OBX rats have a higher SERT density 
and higher level of the tryptophan hydroxylase enzyme 
in the frontal cortex, suggesting the 5-HT hyperinnerva-
tion of that region.46,62 The elevation of the SERT in the 
OBX rats could be related to the proliferation of the glia 
after the neuronal cells die.63 
Cerebral glucose utilization (CGU) represents to-
tal brain energy usage and it was found that there is a 
greater CGU in the terminals than in the cell bodies.64 
However, the CGU in the OBX rats was found to be 
lower than in the sham controls. This could be due to 
the increased levels of the inhibitory neurotransmitters 
(glycine), and the decreased levels of the excitatory 
neurotransmitters (glutamate, aspartate). Other causes 
could be increased 5-HT synthesis and tissue content, 
considering the mostly inhibitory action of 5-HT on 
target neurons and/or a non-specific result of a brain 
injury.65 A micro-dialysis study showed reduced ex-
tracellular 5-HT levels in the dorsal hippocampus and 
basolateral amygdala in rats following OBX surgery.66 
5-HT turnover in OBX rats was elevated in all brain 
regions investigated,66 suggesting the elevation of 5-HT 
synthesis which accords with the autoradiographic meas-
urements.40,41 The administration of D-fenfluramine (a  
5-HT releasing and reuptake blocking drug) and the 
SSRI, fluvoxamine, induced an attenuated increase in 5-
HT levels in the OBX rats.66 Accordingly, this elevation 
in 5-HT would support increased 5-HT synthesis 
rates40,41 and could be the result of an altered control 
mechanism of 5-HT exocytosis. Decreased microdyal-
isis values of 5-HT only accounts for the extracellular  
5-HT, rather than the intracellular. 
Chronic citalopram treatment produced a novel 
CGU (cerebral glucose utilization) pattern, rather than a 
normalized CGU pattern, when compared to the sham 
group.67 The administration of D-fenfluramine reduces 
the rCGU (regional cerebral glucose utilization) in the 
sham, but not the OBX, rats. This finding suggests a 
decreased reactivity of the 5-HT system in OBX rats on 
the fenfluramine challenge. This could be a result of the 
presynaptic (reduced synthesis storage and release, or an 
increased 5-HT clearance) or postsynaptic receptor 
(decrease in density, affinity or sensitivity) changes that 
occur in the OBX rats.68 As previously mentioned, the 
5-HT effect on neuronal activity is mostly inhibitory. It 
has been reported that D-fenfluramine blocks the induc-
tion of the long term potentiation (LTP) which corre-
lates with a reduction in the parameters for glucose 
utilization.69  
Watanabe and colleagues reported that chronic 
treatment (14 day) with 20 mg/kg/day, as opposed to 
10 mg/kg/day, of chronic treatment (14 day) with buspi-
rone (5-HT1A presynaptic agonist, postsynaptic D2 an-
tagonist and adrenergic alpha2 antagonist) decreased  
5-HT synthesis, as measured using α-MTrp autoradio-
graphy. This decrease and normalization of regional  
5-HT synthesis coincides with the normalization of 
open field hyperactivity,27 which was considered to 
represent the antidepressant-equivalent action of buspi-
rone. A reduction in the synthesis following buspirone 
treatment70 was found in many cortical regions (e.g., 
cingulated, frontal, parietal), but not in the ventral teg-
mental area (VTA), DR, MR or superior colliculi (SC). 
This suggests that the 5-HT1A and 5-HT1B receptor sen-
sitivities may be regionally specific. Furthermore, the 
sham rats did not show a reduction in 5-HT synthesis, 
presumably because of receptor desensitization. Others 
reported a dysfunction of 5-HT1A receptors in depressed 
individuals, which is consistent with the findings of  
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5-HT1A receptor alteration in the OBX rats.
70 The den-
sity of the 5-HT1A receptors in the OBX rats was found 
to be lower than in the sham controls. This finding 
could be explained by the elevated tissue 5-HT in OBX 
animals, which produces a desensitization and receptor 
internalization leading to an inhibition of 5-HT synthe-
sis by treatment with a 5-HT1A agonist. An antidepres-
sant treatment (20 mg/kg/day for 14 days) did not pro-
duce a decrease in the 5-HT1A receptor density, but 
rather a fine tuning in some of the limbic brain areas. 
On the other hand, the sham rats showed a dose de-
pendant decrease in 5-HT1A receptor density following 
chronic buspirone treatment. That occurred likely be-
cause of the desensitization (down regulation) effect  
of buspirone on receptor sites.27 However, changes in 
5-HT1A receptor density, per se, will not be sufficient to 
explain the drug action in depression. It was found that 
there is an increase in 5-HT1B and 5-HT2A receptor 
densities in OBX rats when compared to the sham rats 
following chronic buspirone28 administrations. A de-
crease in 5-HT transporter densities occurred in both 
groups.  
 
Noradrenalin System Alterations in OBX Rats 
Several studies showed that noradrenalin brain tissue 
levels were reduced in OBX rats.24,49 Changes in the 
adrenoreceptor function in human depression are simi-
lar to those in OBX rats.24,71 As previously reported, 
desipramine (tricyclic antidepressant) and sertraline 
(SSRI) reversed low levels of noradrenalin in OBX 
rats,24 confirming its the face validity of the OBX 
model. An increase in the adrenoreceptors density in 
the frontal cortex (alpha-2) and in the peripheral blood 
lymphocytes (beta) has been reported.24 A clonidine 
induced hypothermic response, which was reduced in 
the OBX rats, and a growth hormone to clonidine chal-
lenge confirmed reduced function of these receptors in 
OBX rats.24  
 
Dopaminergic System Alterations in OBX Rats  
The deregulation of the dopaminergic system in depres-
sion suggests an important role of this system in depres-
sion. The behavioural effects of OBX resemble psy-
chomotor agitation (e.g., “agitation-like” behaviour). 
This observation has led to the characterization of the 
OBX rats as a model of ‘‘agitated’’ depression.22 As 
measured by micro-dyalisis, OBX rats have higher ex-
tracellular levels of dopamine (DA) in the striatum than 
the sham operated rats, which is likely related to the 
hyperactivity observed in the OBX rats.72 These re-
gional specific differences in the basal levels of dopa-
mine are probably related to the region specific differ-
ences in the densities of the dopamine transporter 
(DAT), a major regulator of dopamine neurotransmis-
sion in the brain, as well as in behavioural changes of 
OBX rats. Some studies suggest a rather prolonged 
disruption in the dopaminergic neurotransmission in the 
OBX rats (2004). Similarly, Lumia et al.22 found a 
reduction in dopamine turnover (HVA/DA ratio; ho-
movanillic acid) in the striatum of OBX rats. It has 
been reported that OBX increases DA D1 and D2 re-
ceptor expression and DA mediated adenylate cyclase 
activity in the olfactory tubercle (OT).73 DA has also 
been implicated in antidepressant treatments, including 
electro convulsive shock therapy (ECS). Acute ECS 
increases striatal concentrations of DOPAC [dihy-
droxyphenylacetic acid] and HVA, but chronic ECS 
decreases these metabolites.74 Lower levels of the do-
pamine metabolite, HVA, are found in the cerebrospi-
nal fluid of depressed suicide attempters.75 High levels 
of DAT are found on dopaminergic cells in the substan-
tia nigra and ventral tegmental area (VTA), as well as 
in the projection areas of the basal ganglia using im-
munocytochemistry.76  
 
Glutamate System Alteration in OBX Rats 
Glutamate is abundant in the brain.77 It plays an impor-
tant role in both the physiology and pathophysiology of 
the central nervous system. Glutamate acts by stimula-
tion ionotropic and metabotropic glutamate receptors.78 
The involvement of group I mGlu receptors (mGlu1 and 
mGlu5) in psychiatric disorders such as depression and 
anxiety has been proposed. Olfactory bulbectomy in-
duces an increase in mGluR1a-immunoreactivity (IR), 
which can be abolished through amitriptyline treatment 
in the hippocampus.79 Similarly, the removal of the 
olfactory bulbs produces a decrease in the level of 
mGlu2/3 receptors in the hippocampus, which is re-
versed by amitriptyline administration. The increase in 
striatal glutamate release in the OBX rats in response to 
novelty exposure (e.g., bright field in the open field test) 
has been associated with glutamate release following 
stress exposure.80 This enhanced glutamate release in 
the striatum of OBX rats after novelty stress could be 
related to elevation of plasma corticosterone by OB, 
because it has been shown that corticosterone affects 
stress-induced glutamate levels in the brain81 and sig-
nificantly higher basal plasma corticosterone levels are 
found in OBX rats when compared to the sham-operated 
controls.82 It has been reported that the mGluR5 antago-
nists, 2-methyl-6-(phenylethynyl)-pyridine (MPEP) and 
3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP), 
exhibit antidepressant activity in the OBX rats.83,84 
Riluzole, a drug currently used for slowing the progres-
sion of amyotrophic lateral sclerosis (ALS), reduced the 
hyperemotional responses in OBX rats and significantly 
lowered the glutamate levels in the frontal cortex after a 
single injection.85 This drug decreases glutamate release 
and increases glutamate uptake. It also enhances the 
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expression of brain derived neurotrophic factor 
(BDNF).85 Because of the exhibited effects, this drug is 
considered as a potential new antidepressant, with the 
glutamatergic system playing a role in mood disorders. 
The N-methyl-D-aspartate glutamate ionotropic receptor 
(NMDA) has been referred to as a locus of action for 
antidepressant medication and its reduced number in the 
cortex and amygdala in OBX rats has been reported.86,87 
Treatment by an NMDA agonist improved learning and 
memory capabilities of OBX rats.88  
 
Acetylcholine System Alteration in OBX Rats 
There is some evidence for a link between depression 
and nicotine acetylcholine receptors (nAChRs).89 The 
antidepressant actions of nicotine and the targeting of 
nAChRs by monoamine re-uptake inhibitors suggest a 
potential role of nAChRs in the aetiology and/or symp-
tomatology of depression. The OBX rats exhibit sig-
nificantly lower acetylcholine levels in the cortex than 
intact and sham operated controls or intact rats.90 Ol-
factory injury causes retrograde degeneration of cho-
linergic fibers in OBX rats. That results in decreased 
cholinergic innervations of the cortex and hippocam-
pus.91 Impairment in learning and memory in OBX rats 
was related to a deficient cholinergic system. Choline 
acetyltransferase (ChAT) fluorescence was found to be 
reduced in the cortex, hippocampus and amygdala of 
OBX rats, but nobiletin (a Citrus Flavonoid) treatment 
rescues OBX-induced cholinergic neurodegeneration 
and is accompanied by improvement in impaired mem-
ory in OBX mice.92 Similarly, it was reported that the 
administration of M1 postsynaptic agonists and M2 
presynaptic antagonists increases performance of OBX 
rats in memory and learning.57 It has also been shown 
that muscarinic receptor densities were reduced in the 
amygdaloid cortex, the basal ganglia, hippocampus, 
hypothalamus, cortex and olfactory regions in OBX 
rats.32 Chronic mianserine and desipramine treatment 
increased the muscarinic receptor density in OBX 
rats.32,93 OBX rats are also less sensitive to the induc-
tion of seizures following pilocarpine administration.94 
The release of acetylcholine from the hippocampus is 
inhibited by 5-HT trough the 5-HT2 receptors.
95 Be-
cause of its cholinergic alterations, the OBX rats are 
also used as a model of Alzheimer’s disease, as there is 
an elevation of beta-amyloid in the rat brain after bul-
bectomy.96  
 
Other Alterations in OBX Rats with Possible, Novel 
Therapeutic Approaches  
Some of the recent results suggest that other systems 
that are altered in OBX rats may serve as possible bio-
logical markers of depression (e.g., genes, neuropep-
tides). Neuropeptide Y, which was linked to depres-
sion,97 was shown to be increased in the amygdala of 
OBX rats.98 It has been proposed that oxidative stress is 
associated with neuronal death and depression.99,100 
Newer research shows that transcranial magnetic stimu-
lation protects cells from oxidative processes in OBX 
rats and serves as a possible method of antidepressant 
treatment. One of the possible explanations of depres-
sion is insufficient production of neurotrophic factors 
(e.g., BDNF) in depressed individuals.101,102 Another 
study has shown that postmortem brains of patients that 
were exposed to antidepressant medication during their 
lifetime had higher hippocampal BDNF levels, relative 
to the post-mortem brains of medication-free normal 
subjects.103 Inconsistent with the findings in depressed 
humans, OBX rats have increased serum BDNF lev-
els.102 A study by Vieyra-Reyes and her colleagues104 
reviewed the assertion that the cessation of smoking 
precipitates depressive symptoms. They also showed 
that olfactory bulbectomy cannot produce depressive-
like symptoms in all strains of rats (e.g., no symptoms 
were developed in the Long Evans rats). Furthermore, 
chronic nicotine intake displayed antidepressant prop-
erties in rodents. They reported an increase of free 
consumption of nicotine in OBX animals.104  
To further understand the complexity of the OBX 
syndrome and its repercussion on neurochemical brain 
systems in the rat brain, it is important to note the in-
volvement of the opioid system in the development of 
the OBX syndrome. Subchronic administration of the 
opioid agonist, SNC80, in OBX rats, reduced hyper-
emotional responses (struggle, fight, attack, and star-
tle), as well as time spent in an open arm maze. These 
effects were not observed in the sham rats. Subchronic 
treatment with the same compound increased levels of 
5-HT and its metabolite, 5-hydroxyindol acetic acid (5-
HIAA), in the frontal cortex, hypothalamus and amyg-
dala in the OBX rats. OBX rats have a reduced number 
of tryptophan hydroxylase cells in the raphe nuclei. The 
administration of SNC80 reversed the OBX-induced 
serotonergic abnormalities in many brain areas.105  
These findings highlight the need for further re-
search to better understand the differences and com-
plexity of human depression as a heterogenic, rather 
than a homogenic, brain disorder.  
 
Flinders Sensitive Line 
Flinders Sensitive Line (FSL) rat is an animal model of 
depression. It has been selectively bred from the Spra-
gue-Dawley strain, based on its supersensitivity to the 
acute hypothermic effect of the cholinesterase inhibitor, 
diisopropyl fluorophosphate (DFP).19,20 The Flinders 
Resistant Line (FRL) was also selectively bred from the 
SPD rats to develop a strain exhibiting a cholinergic 
sub-sensitivity. The original purpose of the breeding 
program that resulted in the development of the FSL 
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and FRL strains was to develop the rat model of cho-
linergic resistance.19,20 However, the cholinergic sensi-
tivity of FRL rats is not different from the SPD rats.23 
Following the subsequent development of the choliner-
gic super-sensitivity theory of depression in humans,106 
it was suggested that FSL rats may be a useful rat model 
of depression. The FRL rats are most often used as the 
normal control strain in the studies of FSL rats.23  
 
Behavioural Characteristics of the FSL Model 
From a behavioural perspective, the FSL rats exhibit 
hypoactivity in the forced swim test,107 a widely used 
screening method for animal models of depression.108 It 
has been suggested that hypoactivity in the forced swim 
test is a reflection of behavioural despair, pointing out 
that the FSL rats may resemble this core feature of hu-
man depression (The Diagnostic and Statistical Manual 
of Mental Disorders-IV; DSM-IV).3 FSL rats are also 
hypoactive in the open field arena,19 which could be 
attributed to psychomotor retardation, but also to nov-
elty-induced anxiety, which suppresses natural explora-
tory behaviour.109 FSL rats had a decreased interaction 
with the con-specifics in the social interaction test,35 
although they did not show anxious behaviour in the 
non-social anxiety test (elevated plus maze).110 Anhedo-
nia (reduced ability to experience pleasure) is one of the 
key features of depression in humans (DSM-IV)3. Nor-
mal animals show a preference for saccharine-sweet-
ened solution, relative to water. The absence of this 
preference is considered to be a sign of anhedonia in 
animal models.111 FSL rats have shown an increased 
preference for the sweetened solution, relative to the 
water, in the basal conditions,107 suggesting a normal 
hedonic response. However, following exposure to 
acute or chronic stress, the preference for the saccha-
rine-sweetened solution in the FSL rats was not main-
tained, while stress had no effect on the sucrose prefer-
ence in the control FRL rats.107 FSL rats have shown the 
normal threshold for intracranial self-stimulation 
(ICSS), another paradigm testing sensitivity to pleas-
ure.112 It is not clear whether the sub-sensitivity of the 
FSL rats to the induction of cocaine-seeking113 is due to 
the elevated hedonic threshold or other reasons. There-
fore, FSL rats have very solid face validity (i.e., resem-
blance of their behavioural phenotype to depressed 
humans). Differences in learning abilities have been 
found in FSL rats, though the direction of the difference 
depends on the tested parameter. The acquisition of the 
learned active avoidance response is significantly 
slower, compared to the FRL rats,23 while the acquisi-
tion of passive avoidance is preserved.20 These findings 
only partially resemble the consistent findings of cogni-
tive impairment in depressed individuals (reviewed by 
Austin et al.114). 
Physiological Characteristics of the FSL Model of 
Depression 
At the physiological level, FSL rats weigh less and 
have lower appetite than the age-matched FRL rats.23 
Weight loss is a common symptom of major depressive 
disorder, although some depressive patients show no 
weight loss or even weight gain during depressive epi-
sodes (DSM-IV).3 Another physiological characteristic 
of the FSL strain that is similar to human depression is 
sleep disruption. Specifically, the rapid eye movement 
(REM) sleep phase has an earlier onset than the FRL 
rats. The percentage of the duration of REM phases, 
relative to total sleep length, is also higher in FSL 
rats,115,116 resembling the findings in the subset of de-
pressed humans.117 The disruption of sleep architecture 
in FSL rats is not surprising, considering the cholinergic 
super-sensitivity of FSL rats and the breadth of evidence 
implicating the role of the cholinergic system in the 
initiation and maintenance of REM sleep (reviewed by 
Shiromani et al.116). A number of immune system al-
terations consistent with those found in depressed pa-
tients have been reported in the FSL rats, such as im-
paired type 1 immune reaction.118  
 
Predictive Validity of the FSL Model of Depression 
The predictive validity of the animal model of psychiat-
ric disease relates to the normalization of aberrant be-
havioural characteristics of the model achieved exclu-
sively using the drugs known to have clinical efficacy in 
human populations suffering from the modelled ill-
ness.119 Different behavioural features of the FSL 
model, immobility in the forced swim being the most 
often tested, have been either normalized or at least 
affected (sildenafil120) following chronic, but not acute, 
treatment with tricyclic antidepressants (imipramine;107 
clomipramine121), selective serotonin reuptake inhibitors 
(SSRIs) (paroxetine;122 fluoxetine35), cholinergic ago-
nists (nicotine123), beta3 adrenoceptor agonists (amibe-
gron124), melatonin receptor agonists (S 20304125), corti-
cotropin releasing factor (CRF) antagonists (CP154, 
523126), neurotrophin (neural growth factor (NG)127), a 
NK2-receptor agonist (saredutant127), and compounds 
which are the components of the second messenger 
signalling systems (inositol128). Thus, behavioural al-
terations in FSL rats are sensitive to clinically tested and 
putative antidepressants of different chemical classes, 
acting through the several neurotransmitter and/or sec-
ond messenger systems in the brain. The sensitivity of 
the behavioural phenotype to chronic, but not acute, 
antidepressant treatment resembles the dynamics of the 
antidepressant efficacy in depressed humans, where 
usually weeks or months of treatment are required be-
fore the onset of clinical improvement. Therefore, it can 
be concluded that the normalization of behaviour in the 
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FSL rats is induced by chronic treatment with different 
antidepressants, suggesting a high predictive validity of 
the FSL rat model of depression.  
 
Neurochemical Characteristics of the FSL Model of 
Depression 
Cholinergic Alterations in the FSL Model of Depression 
Apart from the basic breeding selection criteria for the 
development of the FSL strain, cholinergic super-
sensitivity, and several other alterations were found in 
the cholinergic system of the FSL rats. An increased 
uptake of radioactively labelled choline, the precursor 
of acetylcholine (ACh), in the cortex and higher densi-
ties of muscarinic Ach receptors in the striatum and 
hippocampus were found in the FSL rats.129 However, 
treatment with the muscarinic receptor antagonist, sco-
polamine, did not affect the altered behaviour in the 
FSL rats.130 
 
Serotonergic Alterations in the FSL Model of Depression 
Extensive research has been performed on the parame-
ters of different monoaminergic neurotransmitter sys-
tems in FSL rats. At the level of the serotonergic (5-HT) 
system, higher tissue levels of 5-HT and its metabolite, 
5-HIAA, have been found in the prefrontal cortex, 
hippocampus and hypothalamus of FSL rats, relative to 
SPD controls.36 The tissue concentrations represent the 
contribution from both intra- and extracellular 5-HT, 
but the contribution from each compartment to the  
5-HT levels measured in tissue homogenates cannot be 
distinguished. However, the 5-HT levels in extracellu-
lar space measured using microdyalisis were not differ-
ent in the FSL rats, relative to the SPD controls, sug-
gesting that the differences in the total tissue level of  
5-HT could be attributed to the increased intracellular 
levels of 5-HT in FSL rats. It should be noted that the 
levels of 5-HT and 5-HIAA were normalized following 
an 18 day treatment with a 5 mg/kg/day dose of desip-
ramine.36 
FSL rats have lower 5-HT synthesis rates through-
out the brain, relative to both FRL and SPD rats,131  
as measured using the α-[14C]methyl-L-tryptophan 
(α-MTrp) autoradiographic method (reviewed by Diksic 
and Young132). 5-HT synthesis is normally regulated by 
5-HT1A somatodendritic autoreceptors
133,134 and 5-HT1B 
terminal autoreceptors.135–137 An increase in extracellu-
lar 5-HT levels produced by acute treatment with the 
selective 5-HT reuptake inhibitor (SSRI), citalopram,138 
resulted in a widespread decrease in 5-HT synthesis in 
FSL rats, while producing no change in SPD rats and an 
increase in 5-HT synthesis in FRL rats.139 On the other 
hand, the effect of a chronic citalopram treatment on  
5-HT synthesis in FSL rats was reversed from the acute 
effect, while having no effect on 5-HT synthesis in the 
FRL strain.140 Treatment with buspirone, a 5-HT1A re-
ceptor agonist, produced largely different effects on 
5-HT synthesis in the FSL and FRL rats.141 Acute 
treatment produces no effect on 5-HT synthesis in most 
regions in FSL rats, while both increases (in frontal, 
parietal, sensorimotor and visual cortices) and decreases 
(in dorsal and median raphe nuclei, amygdala, anterior 
olfactory nucleus, ventral hippocampus and substantia 
nigra – pars reticulata) of 5-HT synthesis were found in 
the minority of regions. On the other hand, acute buspi-
rone induced an increase of 5-HT synthesis in the FRL 
rats throughout the brain, with the exception of the locus 
coeruleus, substantia nigra – pars reticulata and dorsal 
thalamus.141 Following chronic treatment with buspi-
rone, the effect on 5-HT synthesis was reversed in both 
strains. In FSL rats, there was a widespread increase of 
5-HT synthesis. Beside the regions showing increase in 
5-HT synthesis following acute treatment, increases 
were now found in the amygdala, ventral thalamus, 
dorsal hippocampus and some striatal regions, while the 
decreased 5-HT following chronic treatment was limited 
to the median and pontine raphe nuclei. In the FRL rats, 
chronic buspirone treatment induced decreased 5-HT 
synthesis in half of the regions tested (including most of 
the cortical regions, nucleus accumbens, medial and 
lateral geniculate and dorsal raphe), but there was oth-
erwise no change in the other half.141 These discrepant 
effects of the drugs acting on the 5-HT system in the 
FSL and FRL rats suggest a different regulation of 5-HT 
synthesis in those strains, which may be due to the dif-
ferent densities of the key receptors regulating 5-HT 
synthesis, such as the lower densities of 5-HT1A and 
higher densities of 5-HT1B in the FSL rats,
29 the receptor 
sites serving as autoreceptors in the cell bodies and 
terminal regions, respectively.  
The acute pharmacological inhibition by an inhibi-
tor of tryptophan hydroxylase (TPH) activation, the key 
enzyme in 5-HT synthesis, did not affect the 5-HT syn-
thesis rates in the terminal brain regions in FSL rats, 
unlike the effect in FRL and SPD rats.140 This suggests 
that the TPH in FSL rats may already be inhibited to a 
certain extent by the high intra-neuronal concentration 
of the end-product (5-HT).142 The high intra-neuronal 
levels of 5-HT may also account for the low 5-HT syn-
thesis rates in the FSL rats.131 The cerebral glucose 
utilization (CGU), an index of neuronal activity,143 
measured by [14C]-2-deoxyglucose autoradiography, is 
shown to be higher in FSL rats, relative to both FRL and 
SPD rats, in most of the brain regions tested.140 This is 
probably due to the decreased serotonergic transmission 
in FSL rats, since the net effect of 5-HT action on the 
target neurons is a decrease in neuronal firing rate.144 
This can be directly translated into lower glucose utili-
zation, considering that glucose represents the principal 
energy source for the neurons and the firing rates are 
shown to be roughly proportional to the CGU.145  
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Dopaminergic Alterations in the FSL Model of Depression 
Higher tissue concentrations (3 to 8-fold) of dopamine 
(DA) and its metabolites, 3,4-dihydroxyphenylacetic 
acid (DOPAC) and homovanilic acid (HVA), have 
been found in the limbic regions and prefrontal cortex 
of FSL rats.36 This finding could be related to the 
higher expression levels of mRNA for tyrosine-
hydroxylase,146 a rate-limiting enzyme in the cate-
cholamine synthesis pathway, in the ventral tegmental 
area (VTA), a region where the cell bodies of the DA 
neurons projecting to the nucleus accumbens (NAc) 
are located. This finding accords with the lower con-
centrations of the vesicular monoamine transporter 2 
(VMAT2) in the NAc and VTA of the FSL rats.147 The 
function of VMAT2 is to store the newly synthesized 
neurotransmitters, as well as the monoamine neuro-
transmitters taken back into the synaptic vesicles, where 
they are protected from enzymatic degradation and 
stored until their release into the synaptic space. One of 
the proposed explanations of the depression-related 
pathophysiology in FSL rats has been the decreased 
release of DA in the NAc.122 DA release in the NAc is 
correlated with the salience of environmental stimuli.148 
Neuroimaging studies in humans have suggested that 
NAc activation also correlates with the subjective report 
of pleasantness of the presented stimuli.149 Therefore, 
decreased DA release in the nucleus accumbens of FSL 
rats may be related to the anhedonia that the FSL rats 
exhibit under stressful conditions.107 The DA release in 
the NAc of FSL rats is not increased following the local 
application of 5-HT, unlike the effect in SPD rats.122 
However, this is normalized following chronic antide-
pressant treatment.122 The extracellular levels of DA in 
the NAc are lower in the FSL rats, which are not af-
fected by blocking the DA transporter using 1-[2-[bis(4-
fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) pipe-
razine (GBR-12909). This suggests that the lower levels 
are a probable consequence of lower DA release, rather 
than increased uptake.113 
 
Noradrenergic Alterations in the FSL Model of Depression 
In parallel to the tissue levels of DA and its metabolites, 
2–3 times higher tissue levels of another catecholamine 
neurotransmitter, norepinephrine (NA), have been found 
in FSL rats, relative to SPD controls, in the median 
raphe, NAc, hippocampus and prefrontal cortex.37 Inter-
estingly, chronic treatment with the norepinephrine 
reuptake inhibitor (NRI), desipramine, normalized the 
tissue levels of NA concurrently with the normalization 
of the altered behavioural parameters in FSL rats (hypo-
activity in the forced swim test).37 
 
Other Neurotransmitter System Alterations in the FSL 
Model of Depression 
FSL rats have lower densities of mGlu2/3 metabotropic 
glutamate receptors in the hippocampus, relative to FRL 
rats. However, in a number of other brain regions (e.g., 
amygdala, hypothalamus and cortical regions), these 
differences were not found.38 FSL rats have shown 
increased binding of benzodiazepines in the striatum 
and hippocampus, coupled with a larger behavioural 
effect of the GABA-ergic drugs, muscimole and diaze-
pam.148  
 
Alterations of the Second Messenger Signalling Systems 
in the FSL Model of Depression 
Differences between the FSL and FRL rats have also 
been found at the intracellular signalling level in the 
CNS. This is consistent with the neurotrophic theory of 
depression,39,139 which states that the depression may be 
a consequence of the altered second messenger signal-
ling mechanisms (i.e., cyclic adenosine 3',5'-monopho-
sphate; cAMP), resulting in lower levels of neurotrophic 
factors (such as brain-derived neurotrophic factor; 
BDNF). This ultimately results in lower cellularity and 
volume in some key brain structures implicated in the 
pathophysiology of depression, including the hippo-
campus. Consistent with the neurotrophic hypothesis of 
depression is the finding of decreased numbers of neu-
rons and synapses in the hippocampus of FSL rats, 
which were normalized following antidepressant treat-
ment with the NA reuptake inhibitor, imipramine. This 
drug also normalized the behavioural features of FSL 
rats.152 However, not all of the findings in the FSL rats 
are consistent with the neurotrophic theory. For exam-
ple, levels of BDNF in the frontal cortex and hippocam-
pus of the FSL rats were not significantly different 
compared to the FRL control rats.153 Indeed, chronic 
treatment with inositol, a precursor of the PIP signalling 
system component, showed the antidepressant effect in 
FSL rats, by reducing immobility in a forced swim 
test.128 Further, chronic treatment with sildenafil, a 
phosphodiesterase type 5 (PDE5) inhibitor, decreased 
immobility in the FSL rats.120 Thus, the treatment im-
pacting directly on one of the intracellular signalling 
systems appeared to be sufficient to normalize the «de-
pressive» behaviour in FSL rats. Increased levels of 
arachidonic acid-containing phosphatidylcholine (AA-
PC) species were found in the hypothalamus and stria-
tum of the FSL rats, and there were decreased levels of 
the docosahexaenoic acid (DHA)-containing species in 
the striatum and prefrontal cortex.154 The fact that the 
FSL strain, originally selected for its cholinergic super-
sensitivity, also shows the supersensitivity of 5-HT1A 
receptors (as measured by the hypothermic effects 
following the acute injection of the selective 5-HT1A 
agonist, buspirone and 8-OH-DPAT),155 further sug-
gests that the FSL rats may differ from normal rats at 
the intracellular signalling level, and are thereby capa-
ble of affecting the multiple neurotransmitter systems 
functions. 
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Depression as a Result of Gene-Environment Inter-
action 
Building on the gene-environment theory of depression, 
which posits that the development of depression is a 
result of the complex interplay between genetic predis-
position and environmental adversities,156,157 a recent 
line of research has exploited the consequences of the 
well established stress-inducing paradigm, maternal 
separation (MS), on the FSL rats and FRL controls. In 
the MS paradigm, pups are separated from the dams for 
between 15 minutes and 6 hours daily, during the first 
two weeks of life.158 In normal rats, this results in the 
development of neurochemical and behavioural changes 
expressed even in adulthood, such as increased anxiety 
and stress-reactivity (reviewed by Holmes et al.159). It 
was presumed that exposing the rats with a genetic 
predisposition for the development of depressive pheno-
type, such as FSL, to maternal separation, would model 
the gene-environment scenario in the development of 
depression in susceptible humans. The study using ma-
ternal separation in FSL and FRL pups has found differ-
ences in the protein expression in several regions impli-
cated in the pathophysiology of depression in humans, 
including the frontal cortex and hippocampus.160 More-
over, chronic treatment with the SSRI, escitalopram, has 
decreased immobility on the forced swim test in the 
non-MS FSL rats, but had no effect on this behavioural 
parameter in the MS FSL rats, suggesting that the cumu-
lative effect of the genetic predisposition to depression 
and early life adversity may result in an altered behav-
ioural phenotype resistant to antidepressant treatment.161 
Differences were also found between the FSL and FRL 
rats in the serum levels of proteins involved in lipid 
metabolism and immunity.162 
Although the straight-forward interpretation of 
these findings is difficult, it appears that stressful condi-
tions during the early developmental phase have differ-
ent effects on brain development, as well as the behav-
ioural phenotype, at the adult stage, in the FSL rats and 
the normal controls.  
 
CONCLUSION 
Inherent weakness of rodent models of most psychiatric 
disorders, especially mood disorders, is that some of the 
core features of these disorders (e.g., excessive feelings 
of guilt or suicidal ideation, in the case of depression) 
are too complex to be induced in rodents and also could 
not be reliably assessed in any animal model due to their 
introspective character. However, OBX and FSL models 
exhibit their validity in two primary ways: 1) the 
physiological and behavioural alterations characterizing 
these models are normalized by the chronic, but not 
acute, treatment with clinically active antidepressants 
targeting various neurochemical systems; and 2) the 
same alterations are not changed following treatment 
with psychotropic drugs other than antidepressants. This 
makes the FSL and OBX models useful tools for drug 
candidate screening in the pharmaceutical industry. 
Nevertheless, concerns have been raised that relying on 
existing models as screening tools could result in false-
negative findings when testing the compounds with the 
mechanisms of action different from the present antide-
pressants.  
Further, it can be stated that there is a great need 
for the study of depression and its treatment in good 
animal models of depression, rather than studying 
treatments in normal rats, as one can then use a homo-
geneous population group and any conclusions drawn 
can more likely be correlated to some human depres-
sion. The data summarized also suggest that studies of 
brain regional 5-HT synthesis, as one of the most impor-
tant presynaptic processes, are very important for a 
better understanding of depression itself and neuro-
chemical changes produced by treatments. 
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